+
データを開く
-
基本情報
| 登録情報 | データベース: PDB / ID: 8vqe | ||||||
|---|---|---|---|---|---|---|---|
| タイトル | Homodimeric structure of HER2 S310F extracellular region | ||||||
要素 | Receptor tyrosine-protein kinase erbB-2/hIgG1 Fc domain fusion | ||||||
キーワード | SIGNALING PROTEIN / Receptor tyrosine kinase / HER2 / oncogenic mutation | ||||||
| 機能・相同性 | 機能・相同性情報negative regulation of immature T cell proliferation in thymus / ERBB3:ERBB2 complex / ERBB2-ERBB4 signaling pathway / GRB7 events in ERBB2 signaling / RNA polymerase I core binding / immature T cell proliferation in thymus / semaphorin receptor complex / regulation of microtubule-based process / ErbB-3 class receptor binding / motor neuron axon guidance ...negative regulation of immature T cell proliferation in thymus / ERBB3:ERBB2 complex / ERBB2-ERBB4 signaling pathway / GRB7 events in ERBB2 signaling / RNA polymerase I core binding / immature T cell proliferation in thymus / semaphorin receptor complex / regulation of microtubule-based process / ErbB-3 class receptor binding / motor neuron axon guidance / Sema4D induced cell migration and growth-cone collapse / PLCG1 events in ERBB2 signaling / ERBB2-EGFR signaling pathway / ERBB2 Activates PTK6 Signaling / enzyme-linked receptor protein signaling pathway / neurotransmitter receptor localization to postsynaptic specialization membrane / neuromuscular junction development / positive regulation of Rho protein signal transduction / ERBB2-ERBB3 signaling pathway / Drug-mediated inhibition of ERBB2 signaling / Resistance of ERBB2 KD mutants to trastuzumab / Resistance of ERBB2 KD mutants to sapitinib / Resistance of ERBB2 KD mutants to tesevatinib / Resistance of ERBB2 KD mutants to neratinib / Resistance of ERBB2 KD mutants to osimertinib / Resistance of ERBB2 KD mutants to afatinib / Resistance of ERBB2 KD mutants to AEE788 / Resistance of ERBB2 KD mutants to lapatinib / Drug resistance in ERBB2 TMD/JMD mutants / positive regulation of transcription by RNA polymerase I / positive regulation of MAP kinase activity / ERBB2 Regulates Cell Motility / semaphorin-plexin signaling pathway / oligodendrocyte differentiation / PI3K events in ERBB2 signaling / positive regulation of protein targeting to membrane / regulation of angiogenesis / regulation of ERK1 and ERK2 cascade / Schwann cell development / coreceptor activity / Signaling by ERBB2 / TFAP2 (AP-2) family regulates transcription of growth factors and their receptors / myelination / transmembrane receptor protein tyrosine kinase activity / GRB2 events in ERBB2 signaling / positive regulation of cell adhesion / SHC1 events in ERBB2 signaling / Downregulation of ERBB2:ERBB3 signaling / cell surface receptor protein tyrosine kinase signaling pathway / basal plasma membrane / Constitutive Signaling by Overexpressed ERBB2 / cellular response to epidermal growth factor stimulus / peptidyl-tyrosine phosphorylation / positive regulation of translation / positive regulation of epithelial cell proliferation / neuromuscular junction / phosphatidylinositol 3-kinase/protein kinase B signal transduction / wound healing / Signaling by ERBB2 TMD/JMD mutants / receptor protein-tyrosine kinase / Signaling by ERBB2 ECD mutants / receptor tyrosine kinase binding / Signaling by ERBB2 KD Mutants / cellular response to growth factor stimulus / ruffle membrane / Downregulation of ERBB2 signaling / epidermal growth factor receptor signaling pathway / neuron differentiation / Constitutive Signaling by Aberrant PI3K in Cancer / transmembrane signaling receptor activity / PIP3 activates AKT signaling / myelin sheath / heart development / presynaptic membrane / PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling / RAF/MAP kinase cascade / positive regulation of cell growth / protein tyrosine kinase activity / basolateral plasma membrane / early endosome / cell surface receptor signaling pathway / cell population proliferation / protein phosphorylation / receptor complex / positive regulation of MAPK cascade / endosome membrane / intracellular signal transduction / apical plasma membrane / protein heterodimerization activity / signaling receptor binding / negative regulation of apoptotic process / perinuclear region of cytoplasm / signal transduction / nucleoplasm / ATP binding / identical protein binding / nucleus / membrane / plasma membrane / cytosol 類似検索 - 分子機能 | ||||||
| 生物種 | Homo sapiens (ヒト) | ||||||
| 手法 | 電子顕微鏡法 / 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 2.67 Å | ||||||
データ登録者 | Bang, I. / Koide, S. | ||||||
| 資金援助 | 1件
| ||||||
引用 | ジャーナル: Nat Chem Biol / 年: 2025タイトル: Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain. 著者: Injin Bang / Takamitsu Hattori / Nadia Leloup / Alexis Corrado / Atekana Nyamaa / Akiko Koide / Ken Geles / Elizabeth Buck / Shohei Koide / ![]() 要旨: Oncogenic mutations in the extracellular domain (ECD) of cell-surface receptors could serve as tumor-specific antigens that are accessible to antibody therapeutics. Such mutations have been ...Oncogenic mutations in the extracellular domain (ECD) of cell-surface receptors could serve as tumor-specific antigens that are accessible to antibody therapeutics. Such mutations have been identified in receptor tyrosine kinases including HER2. However, it is challenging to selectively target a point mutant, while sparing the wild-type protein. Here we developed antibodies selective to HER2 S310F and S310Y, the two most common oncogenic mutations in the HER2 ECD, via combinatorial library screening and structure-guided design. Cryogenic-electron microscopy structures of the HER2 S310F homodimer and an antibody bound to HER2 S310F revealed that these antibodies recognize the mutations in a manner that mimics the dimerization arm of HER2 and thus inhibit HER2 dimerization. These antibodies as T cell engagers selectively killed a HER2 S310F-driven cancer cell line in vitro, and in vivo as a xenograft. These results validate HER2 ECD mutations as actionable therapeutic targets and offer promising candidates toward clinical development. | ||||||
| 履歴 |
|
-
構造の表示
| 構造ビューア | 分子: Molmil Jmol/JSmol |
|---|
-
ダウンロードとリンク
-
ダウンロード
| PDBx/mmCIF形式 | 8vqe.cif.gz | 251.2 KB | 表示 | PDBx/mmCIF形式 |
|---|---|---|---|---|
| PDB形式 | pdb8vqe.ent.gz | 161.7 KB | 表示 | PDB形式 |
| PDBx/mmJSON形式 | 8vqe.json.gz | ツリー表示 | PDBx/mmJSON形式 | |
| その他 | その他のダウンロード |
-検証レポート
| 文書・要旨 | 8vqe_validation.pdf.gz | 1 MB | 表示 | wwPDB検証レポート |
|---|---|---|---|---|
| 文書・詳細版 | 8vqe_full_validation.pdf.gz | 1 MB | 表示 | |
| XML形式データ | 8vqe_validation.xml.gz | 38.4 KB | 表示 | |
| CIF形式データ | 8vqe_validation.cif.gz | 56.4 KB | 表示 | |
| アーカイブディレクトリ | https://data.pdbj.org/pub/pdb/validation_reports/vq/8vqe ftp://data.pdbj.org/pub/pdb/validation_reports/vq/8vqe | HTTPS FTP |
-関連構造データ
| 関連構造データ | ![]() 43440MC ![]() 8vqdC C: 同じ文献を引用 ( M: このデータのモデリングに利用したマップデータ |
|---|---|
| 類似構造データ | 類似検索 - 機能・相同性 F&H 検索 |
-
リンク
-
集合体
| 登録構造単位 | ![]()
|
|---|---|
| 1 |
|
-
要素
| #1: タンパク質 | 分子量: 99277.641 Da / 分子数: 2 / 変異: S310F / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 遺伝子: ERBB2, HER2, MLN19, NEU, NGL / 発現宿主: Homo sapiens (ヒト) / 参照: UniProt: P04626, receptor protein-tyrosine kinase#2: 多糖 | 研究の焦点であるリガンドがあるか | N | Has protein modification | Y | |
|---|
-実験情報
-実験
| 実験 | 手法: 電子顕微鏡法 |
|---|---|
| EM実験 | 試料の集合状態: PARTICLE / 3次元再構成法: 単粒子再構成法 |
-
試料調製
| 構成要素 | 名称: Homodimeric structure of Her2 S310F fused to Fc domain タイプ: COMPLEX 詳細: Homodimeric structure of HER2 S310F is obtained by fusing it to Fc domain, although the density for Fc domain is not clear. Entity ID: #1 / 由来: RECOMBINANT | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 分子量 | 値: 200 kDa/nm / 実験値: YES | ||||||||||||||||||||
| 由来(天然) | 生物種: Homo sapiens (ヒト) | ||||||||||||||||||||
| 由来(組換発現) | 生物種: Homo sapiens (ヒト) | ||||||||||||||||||||
| 緩衝液 | pH: 7.5 詳細: 20mM Tris, 150mM NaCl, 0.7mM Fluorinated octyl maltoside | ||||||||||||||||||||
| 緩衝液成分 |
| ||||||||||||||||||||
| 試料 | 包埋: NO / シャドウイング: NO / 染色: NO / 凍結: YES | ||||||||||||||||||||
| 試料支持 | グリッドの材料: COPPER / グリッドのサイズ: 300 divisions/in. / グリッドのタイプ: Quantifoil R0.6/1 | ||||||||||||||||||||
| 急速凍結 | 装置: FEI VITROBOT MARK IV / 凍結剤: ETHANE / 湿度: 95 % / 凍結前の試料温度: 277.15 K / 詳細: Vitrified |
-
電子顕微鏡撮影
| 実験機器 | ![]() モデル: Titan Krios / 画像提供: FEI Company |
|---|---|
| 顕微鏡 | モデル: FEI TITAN KRIOS |
| 電子銃 | 電子線源: FIELD EMISSION GUN / 加速電圧: 300 kV / 照射モード: FLOOD BEAM |
| 電子レンズ | モード: BRIGHT FIELD / 最大 デフォーカス(公称値): 2100 nm / 最小 デフォーカス(公称値): 700 nm |
| 撮影 | 電子線照射量: 51.89 e/Å2 フィルム・検出器のモデル: GATAN K3 BIOQUANTUM (6k x 4k) |
-
解析
| EMソフトウェア |
| |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTF補正 | タイプ: PHASE FLIPPING AND AMPLITUDE CORRECTION | |||||||||||||||||||||||||||||||||||
| 3次元再構成 | 解像度: 2.67 Å / 解像度の算出法: FSC 0.143 CUT-OFF / 粒子像の数: 110685 / 対称性のタイプ: POINT | |||||||||||||||||||||||||||||||||||
| 原子モデル構築 | プロトコル: FLEXIBLE FIT / 空間: REAL | |||||||||||||||||||||||||||||||||||
| 原子モデル構築 | PDB-ID: 7MN6 PDB chain-ID: B / Accession code: 7MN6 / Chain residue range: 24-542 / Pdb chain residue range: 24-542 / Source name: PDB / タイプ: experimental model | |||||||||||||||||||||||||||||||||||
| 拘束条件 |
|
ムービー
コントローラー
万見について




Homo sapiens (ヒト)
引用



PDBj











FIELD EMISSION GUN
